Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC0471-0119
- Development stage
- Phase 1
- Lead developer
- Novo Nordisk
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous (via Infusion Pump)
01
Overview
NNC0471-0119 is a novel, rapid-acting insulin analogue developed for the treatment of type 1 diabetes mellitus. It is designed to be administered via continuous subcutaneous infusion using an insulin pump. The drug acts as an agonist of the insulin receptor, mimicking endogenous human insulin to lower blood glucose levels by promoting cellular uptake of glucose and inhibiting hepatic glucose production. Clinical studies are evaluating its pharmacokinetics, pharmacodynamics, safety, and efficacy compared to existing rapid-acting insulins such as insulin aspart (Fiasp). Multiple formulations have been tested in early-phase clinical trials[1][3][4][5].
- Other names
- insulin NNC0471-0119NNC0471 0119 HNNC-0471 0119 HNNC 0471 0119 H
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on NNC0471-0119.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC0471-0119.